Image ME kit June 12 2013
July 25, 2011
- New England Peptide (NEP) and the Atlantic Cancer Research Institute (ACRI) announced today that they have jointly submitted a patent application for cancer-related peptide reagents which have the potential to deliver breakthroughs in cancer diagnostics and more individualized therapies for cancer patients.

One of the hallmarks of cancer cells is their high propensity to "bud off" their cellular material into small particles called microvesicles and exosomes. These particles carry a variety of information about the parent cancer cell that recently has become a primary focus of research. Early findings from cell cultures grown in the lab indicate vast potential, but to maximize the overall benefit, scientists need to use cells from real life samples. While this has previously proven to be difficult, the reagents developed by NEP and ACRI will allow real life samples to be used in a simple and economical manner for the first time.

"With these peptides we are able to capture circulating microvesicles and exosomes intact from a variety of body fluids," said Dr. Steve Griffiths, researcher at ACRI and co-inventor of the new peptides. "Existing methods give comparatively lower yields and thus present missed opportunities for detection and characterization."

"The mRNA, miRNA, and protein information found in microvesicles and exosomes thus far have already revealed known cancer bio-markers," said co-inventor Scott Lewis, Director, Antibody Division at NEP. "Further research enabled by these reagents will be extremely useful in creating profiles of specific cancer types, as well as providing insight into how and why some cancers progress into being lethal and others do not."

"Further research and formulation is still required, but our vision is very much focused on releasing these peptides as products in a variety of formats in the coming years," said Dave Robinson, NEP's CEO. "We are excited to directly participate in contributing to improvements in detection and diagnoses of cancer, which will lead to better personalized medicine for treatment."

"This is an ideal partnership for ACRI," said Dr. Rodney Ouellette, President and Scientific Director at ACRI. "We are very pleased to be working with a commercial partner with whom we can commercialize our discoveries and transfer scientific innovations towards patient care."

Atlantic Cancer Research Institute (ACRI)

The Atlantic Cancer Research Institute (ACRI) is a non-profit organization founded in 1998 and housed at the Dr. Georges-L. Dumont University Hospital Centre in Moncton, New Brunswick. Thanks to its unique expertise, the ACRI has become a true centre of excellence in cancer research. Scientists are working with partners in Canada and around the world to discover the genetic origins of cancer and pursuing three main areas of development: early screening; enhanced diagnosis, and targeted treatment. More information at or on Facebook Atlantic Cancer Research.

New England Peptide (NEP)

New England Peptide, founded in 1998, designs and produces custom peptides and polyclonal antibodies for drug and vaccine discovery organizations worldwide. Headquartered in the Boston metro area in Gardner, Mass., the company's chemists and immunological experts specialize in delivering a full range of services for biotech and pharmaceutical applications.

Peptides are small proteins that play key roles in biochemical regulation of all life systems, helping to fight diseases as diverse as cancer, diabetes, obesity and HIV/AIDS. Peptides' inherent low toxicity and high potency, coupled with improved drug delivery methods and enhanced manufacturing capabilities, are fueling a surge in research and clinical use.

Excipio Technologies Inc.

35 Providence Street
Moncton, New Brunswick
E1C 8X3

METM Kit product information:

Business Development Contact:
Remi Richard
Business Development Agent
Phone : +1 506 869 2048
Fax : +1 506 862 7571

Unlock the diagnostic potential of exosomes

Increase the specificity and sensitivity of your biofluid-based molecular diagnostic assays with Vn96. The Vn96 platform technology can give you access to improved clinical diagnostics directly on site or at point-of-care with faster, more specific and efficient exosome isolation. All while using your existing infrastructure, minimizing your isolation time to less than an hour and eliminating the need for ultracentrifugation or expensive antibodies and filtration methods.
logo iarc logo nep

Follow us

icon facebook off icon linkedin off icon youtube off icon google off icon twitter off